VEGFA and age-related macular degeneration: The greatest advancement in the clinical approach to AMD has been the introduction of antiangiogenic therapies for wet AMD56,57; the most widely used is the vascular endothelial growth factor–inhibiting monoclonal antibodies bevacizumab and ranibizumab.58 Wet AMD, the less common form of the disease, affects vision more severely, and, although great benefit has been derived from this therapy, it only halts disease progression and does not prevent onset, nor does it reverse damage already caused to the vision.